RU2017122817A - Camkk1 в качестве нового регенеративного терапевтического средства - Google Patents
Camkk1 в качестве нового регенеративного терапевтического средства Download PDFInfo
- Publication number
- RU2017122817A RU2017122817A RU2017122817A RU2017122817A RU2017122817A RU 2017122817 A RU2017122817 A RU 2017122817A RU 2017122817 A RU2017122817 A RU 2017122817A RU 2017122817 A RU2017122817 A RU 2017122817A RU 2017122817 A RU2017122817 A RU 2017122817A
- Authority
- RU
- Russia
- Prior art keywords
- camkk1
- tissue
- organ
- cells
- preceding paragraphs
- Prior art date
Links
- 102100021535 Calcium/calmodulin-dependent protein kinase kinase 1 Human genes 0.000 title claims 18
- 101000971625 Homo sapiens Calcium/calmodulin-dependent protein kinase kinase 1 Proteins 0.000 title claims 18
- 230000001172 regenerating effect Effects 0.000 title claims 3
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 23
- 210000000056 organ Anatomy 0.000 claims 13
- 210000001519 tissue Anatomy 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 7
- 230000000302 ischemic effect Effects 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 101150046623 Dab2 gene Proteins 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003636 conditioned culture medium Substances 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000013600 plasmid vector Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002175 menstrual effect Effects 0.000 claims 1
- 108091059434 miR-45 stem-loop Proteins 0.000 claims 1
- 108091029227 miR-45-1 stem-loop Proteins 0.000 claims 1
- 108091085809 miR-45-2 stem-loop Proteins 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 210000005059 placental tissue Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086026P | 2014-12-01 | 2014-12-01 | |
| US62/086,026 | 2014-12-01 | ||
| PCT/US2015/063118 WO2016089826A1 (en) | 2014-12-01 | 2015-12-01 | Camkk1 as a novel regenerative therapeutic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017122817A true RU2017122817A (ru) | 2019-01-10 |
| RU2017122817A3 RU2017122817A3 (cg-RX-API-DMAC7.html) | 2019-06-11 |
Family
ID=56092307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017122817A RU2017122817A (ru) | 2014-12-01 | 2015-12-01 | Camkk1 в качестве нового регенеративного терапевтического средства |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273208B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3940068A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6893873B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102236843B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015355188B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007055C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2017001390A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20170301A (cg-RX-API-DMAC7.html) |
| IL (2) | IL252612B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2017122817A (cg-RX-API-DMAC7.html) |
| UA (1) | UA124450C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016089826A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016089826A1 (en) | 2014-12-01 | 2016-06-09 | Summa Health | Camkk1 as a novel regenerative therapeutic |
| EP3781182A4 (en) | 2018-04-18 | 2021-11-17 | Summa Health | COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426206B1 (en) * | 2000-11-13 | 2002-07-30 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| WO2002072115A2 (en) | 2001-03-09 | 2002-09-19 | Board Of Regents, The University Of Texas System | Vectors, compositions and methods for treating a vascular disorder |
| US7776564B2 (en) | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| US7764995B2 (en) * | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US8173118B2 (en) * | 2004-07-30 | 2012-05-08 | Mayo Foundation For Medical Education And Research | Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin |
| CN101103101B (zh) | 2004-09-24 | 2012-10-10 | 成血管细胞系统公司 | 增强间充质前体细胞（mpc）的增生和/或存活的方法 |
| US20090246179A1 (en) | 2008-02-11 | 2009-10-01 | The Cleveland Clinic Foundation | Method of treating myocardial injury |
| EP2687219A1 (en) * | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
| EP3039124A1 (en) * | 2013-08-29 | 2016-07-06 | Stempeutics Research Private Limited | Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof |
| WO2016089826A1 (en) * | 2014-12-01 | 2016-06-09 | Summa Health | Camkk1 as a novel regenerative therapeutic |
| HK1246180A1 (zh) | 2014-12-31 | 2018-09-07 | Celgene Corporation | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
-
2015
- 2015-12-01 WO PCT/US2015/063118 patent/WO2016089826A1/en not_active Ceased
- 2015-12-01 KR KR1020177018031A patent/KR102236843B1/ko active Active
- 2015-12-01 KR KR1020227037365A patent/KR102610068B1/ko active Active
- 2015-12-01 EP EP21182570.8A patent/EP3940068A1/en active Pending
- 2015-12-01 JP JP2017530094A patent/JP6893873B2/ja active Active
- 2015-12-01 RU RU2017122817A patent/RU2017122817A/ru not_active Application Discontinuation
- 2015-12-01 EP EP15864736.2A patent/EP3227441B1/en active Active
- 2015-12-01 CA CA3007055A patent/CA3007055C/en active Active
- 2015-12-01 UA UAA201706834A patent/UA124450C2/uk unknown
- 2015-12-01 KR KR1020217001921A patent/KR102460983B1/ko active Active
- 2015-12-01 AU AU2015355188A patent/AU2015355188B2/en active Active
- 2015-12-01 CR CR20170301A patent/CR20170301A/es unknown
-
2017
- 2017-05-31 US US15/610,540 patent/US11273208B2/en active Active
- 2017-05-31 CL CL2017001390A patent/CL2017001390A1/es unknown
- 2017-06-01 IL IL252612A patent/IL252612B/en unknown
-
2021
- 2021-03-02 JP JP2021032502A patent/JP2021098717A/ja active Pending
- 2021-06-27 IL IL284408A patent/IL284408B/en unknown
-
2022
- 2022-02-08 US US17/667,375 patent/US20220233653A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021098717A (ja) | 2021-07-01 |
| EP3227441B1 (en) | 2021-06-30 |
| WO2016089826A1 (en) | 2016-06-09 |
| EP3227441A1 (en) | 2017-10-11 |
| US20170340712A1 (en) | 2017-11-30 |
| KR20210010662A (ko) | 2021-01-27 |
| CA3007055A1 (en) | 2016-06-09 |
| CA3007055C (en) | 2023-08-01 |
| IL252612B (en) | 2021-07-29 |
| UA124450C2 (uk) | 2021-09-22 |
| KR102460983B1 (ko) | 2022-10-31 |
| JP6893873B2 (ja) | 2021-06-23 |
| KR102236843B1 (ko) | 2021-04-07 |
| CR20170301A (es) | 2018-02-01 |
| EP3940068A1 (en) | 2022-01-19 |
| US11273208B2 (en) | 2022-03-15 |
| KR20220151004A (ko) | 2022-11-11 |
| AU2015355188A1 (en) | 2017-07-20 |
| RU2017122817A3 (cg-RX-API-DMAC7.html) | 2019-06-11 |
| AU2015355188B2 (en) | 2021-08-26 |
| KR20170088988A (ko) | 2017-08-02 |
| BR112017011490A2 (pt) | 2018-02-27 |
| JP2018502838A (ja) | 2018-02-01 |
| CL2017001390A1 (es) | 2018-05-11 |
| IL284408B (en) | 2022-06-01 |
| KR102610068B1 (ko) | 2023-12-06 |
| US20220233653A1 (en) | 2022-07-28 |
| IL252612A0 (en) | 2017-07-31 |
| EP3227441A4 (en) | 2018-08-15 |
| IL284408A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shafei et al. | Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction | |
| JP2016515533A5 (cg-RX-API-DMAC7.html) | ||
| Tarui et al. | Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial | |
| Xu et al. | Circulating mesenchymal stem cells and their clinical implications | |
| Holfeld et al. | Shockwave therapy differentially stimulates endothelial cells: implications on the control of inflammation via toll-like receptor 3 | |
| Comella et al. | Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy | |
| Compagna et al. | Cell therapy in patients with critical limb ischemia | |
| Dai et al. | Chronic AMD3100 antagonism of SDF-1α–CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction | |
| Chen et al. | Low-intensity pulsed ultrasound promotes mesenchymal stem cell transplantation-based articular cartilage regeneration via inhibiting the TNF signaling pathway | |
| Zhao et al. | Mesenchymal stem cell biodistribution, migration, and homing in vivo | |
| Tang et al. | VEGF-A promotes cardiac stem cell engraftment and myocardial repair in the infarcted heart | |
| Wang et al. | Distinct patterns of histone modifications at cardiac-specific gene promoters between cardiac stem cells and mesenchymal stem cells | |
| JP2017530151A5 (cg-RX-API-DMAC7.html) | ||
| Cohn Yakubovich et al. | Systemic administration of mesenchymal stem cells combined with parathyroid hormone therapy synergistically regenerates multiple rib fractures | |
| Fidelis-de-Oliveira et al. | Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts | |
| Ohnishi et al. | Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure | |
| JP2018502838A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Ultrasound-targeted microbubble destruction enhances delayed BMC delivery and attenuates post-infarction cardiac remodelling by inducing engraftment signals | |
| Turksen | Adult stem cells and cardiac regeneration | |
| Ratajczak | Circulating stem cells in physiology and pathology-recent studies published in stem cell reviews and reports | |
| Trivisonno et al. | Adipose tissue: from energy reservoir to a source of cells for epithelial tissue engineering | |
| KR101555941B1 (ko) | 후코이단을 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제 | |
| Gennari et al. | Emerging treatment options for refractory angina pectoris: ranolazine, shock wave treatment, and cell-based therapies | |
| US20100226894A1 (en) | Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood | |
| Taylor | The use of biologics in the management of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200421 |